Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries

Table 5

Biochemistry, imaging, bronchoscopy, and pathology findings in bronchial NET patients managed at our institution divided in chronological time frames.

	1995–2000	2001–2005	2006–2010	2011–2015
	Chromogranin A (plasma)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
0 (0%)		0 (0%)	1 (5.0%)	0 (0%)
KI-67 (histology)	0 (0%)	0 (0%)	3 (15.0%)	13 (68.4%)
Mitotic count (histology)	2 (40.0%)	0 (0%)	12 (60.0%)	13 (68.4%)
Synaptophysin (histology)	3 (60.0%)	0 (0%)	12 (60.0%)	13 (68.4%)
Chromogranin A (histology)	3 (60.0%)	0 (0%)	8 (40.0%)	14 (73.7%)
CD 56 (histology)	0 (0%)	0 (0%)	2 (10.0%)	9 (47.4%)
Bronchoscopy	5 (100%)	2 (100%)	20 (100%)	19 (100%)
	0 (0%)	0 (0%)	3 (15.0%)	1 (5.3%)
CT	5 (100%)	2 (100%)	20 (100%)	19 (100%)
	4 (80.0%)	1 (50.0%)	13 (65.0%)	12 (63.2%)
Chest X-ray	5 (100%)	2 (100%)	20 (100%)	19 (100%)
	5 (100%)	2 (100%)	19 (95.0%)	17 (89.5%)
^18F-FDG PET	0 (0%)	0 (0%)	10 (50.0%)	8 (42.1%)
	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Octreoscan	0 (0%)	0 (0%)	1 (5.0%)	3 (15.8%)
	0 (0%)	0 (0%)	2 (10.0%)	0 (0%)

: number of patients.